NewsNovember 21, 2024
PHC Group Named a Top 100 Healthcare Technology Company of 2024 by The Healthcare Technology Report
— Award recognizes PHC Group brands for wide-ranging impact on diagnostics, life sciences, clinical testing, healthcare IT, and diabetes management —
TOKYO, JAPAN, November 21, 2024 – PHC Holdings Corporation (headquarters: Chiyoda-ku, Tokyo, Japan, President & CEO: Kyoko Deguchi, hereafter PHC Group), a global healthcare company dedicated to providing precision technology that powers the future of healthcare, has been named to the “Top 100 Healthcare Technology Companies of 2024*1” list published by The Healthcare Technology Report*2, a leading healthcare technology industry publication.
Each year, The Healthcare Technology Report recognizes companies and executives that create innovative solutions to the most pressing issues in healthcare. The Top 100 Healthcare Technology Companies list reflects an industry cross-section of companies making an impact from R&D to patient care, and winners from global pharmaceutical companies to consumer health startups.
PHC Group is comprised of a network of established companies that are leaders in their respective fields, with $2.2B in total annual revenue. PHC Group companies have been providing innovative precision and digital health solutions for more than 50 years to advance research, diagnosis, treatment, and prevention of disease. PHC Group’s business segments and trusted brands include:
• Diabetes Management: Providing cutting-edge glucose monitoring technology.
º Ascensia Diabetes Care blood glucose monitoring products are used by an estimated 10 million people worldwide. Ascensia has partnered with Senseonics to deliver Eversense, the world’s first long-term implantable continuous glucose monitoring (CGM) systems.
• Healthcare Solutions: Driving digital transformation in medical care.
º Wemex has Japan’s largest market share for medical-receipt computers and electronic medical record systems in clinics and pharmacies.
º LSI Medience provides services in clinical testing including cancer diagnostics, genetic testing, and sports doping testing.
º Mediford supports drug research and development, from basic development to clinical trials.
• Diagnostics & Life Sciences: Contributing to the early detection and treatment of disease.
º Epredia offers precision cancer diagnostic solutions to improve the laboratory workflow and support more efficient and accurate decisions.
º PHCbi award-winning ultra-low temperature freezers support research laboratories with industry-leading energy-saving performance.
º PHC IVD provides highly accurate diagnostic and compact POCT (point of care testing) devices.
Kyoko Deguchi, President and CEO of PHC Group, said, “At PHC Group, we believe that nothing is more important than improving people’s health. We are committed to creating synergies across our interconnected global businesses that can contribute to higher quality, better access, and improved cost-effectiveness of healthcare. Being named a Top Healthcare Technology Company of 2024 is an honor, and recognition that our brands are helping people make better healthcare decisions and deliver higher-quality care.”
*1 https://thehealthcaretechnologyreport.com/the-top-100-healthcare-technology-companies-of-2024/
*2 https://thehealthcaretechnologyreport.com/
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com